PharmaTalkRadio

This 8 minute podcast summarizes what you can expect at the 4th annual IO Combinations 360° conference. This conference provides the latest data impacting immuno-oncology combinations and patient treatment with perspectives from science, clinical and business.

The conference takes place June 20-21, 2019 at the Wyndham Philadelphia Historic District, Philadelphia, PA. For more information please visit www.theconferenceforum.org or contact us at [email protected]

Dr Marco Ruella, Assistant Professor and Scientific Director Lymphoma Program, Division of Hematology and Oncology, Department of Medicine and Center for Cellular Immunotherapies (CCI), Perelman School of Medicine, University of Pennsylvania focuses on the next steps for CAR-T therapy for cancer, discussing the novel approaches that are being developing in Dr Carl June’s lab including CAR-T combinations with small molecules and gene-editing.

Save the date for IO Combinations 360° happening June 20-21, 2019 at the Wyndham Historic District Hotel, Philadelphia, PA and for IO360° happening February 26-28, 2020 at the Crowne Plaza Times Square in New York City.

The hardest thing to figure out now is what interventions and combinations make the most sense in which patients and how to combine all these emerging modalities in a way that is cost effective, benefits patients and unfolds in our lifetime. There are hypothesis on what technologies should be explored together, however very few companies have all the relevant skills, reagents or product candidates in one setting, so it requires collaboration to generate the most powerful combinations and sequence of interventions. This overview talk, followed by a panel will delve into the following:

What is the underlying pathobiology and how it is similar from patient to patient and how it is different in individuals?What interventions make the most sense and how to get the right patient into the studies to test your hypothesis?How can we build an integrated suite of tools to ask and answer all the  relevant questions to appropriately characterize patients?How can we develop something cost effective that doesn’t necessarily require 100K worth of diagnostic tests in every patient?

Save the date for IO Combinations 360° happening June 20-21, 2019 at the Wyndham Historic District Hotel, Philadelphia, PA and for IO360° happening February 26-28, 2020 at the Crowne Plaza Times Square in New York City.

In this panel, moderated by Dr Axel Hoos, GSK, individuals from large pharma and biotech business development leads discuss decision-making when it comes to partnering and collaborations in today’s IO environment.

What is the current nature and types of partnerships being done in IO?Is dealmaking and partnerships evolving due to the need for IO combinations? How so?What is the balance between in house R&D and external innovation in IO?What is the decision making regarding exclusive licensing and “no strings attached” partnerships?

Save the date for IO Combinations 360° happening June 20-21, 2019 at the Wyndham Historic District Hotel, Philadelphia, PA and for IO360° happening February 26-28, 2020 at the Crowne Plaza Times Square in New York City.

This panel, moderated by Dr Priti Hegde, Genentech, discusses the following:

How can biomarkers act as a tool for understanding the biology at a level that is sufficient for making decisions around combinations?What are the potential biomarkers that can help predict if a patient will respond to combinations?Once a biomarker is identified in terms of biology, been measured and the technology platform identified to meet those measures, how is the biomarker developed to the level of clinical grade that meets approval?How do we validate diagnostics in IO/combinations?How do you satisfy regulators?Are there other biomarkers in development?What are the implications for intervention?Are biomarkers and companion diagnostics crucial for rational combination success?

Save the date for IO Combinations 360° happening June 20-21, 2019 at the Wyndham Historic District Hotel, Philadelphia, PA and for IO360° happening February 26-28, 2020 at the Crowne Plaza Times Square in New York City.

In this podcast, Dr Gregory Goldmacher, Executive Director, Translational Biomarkers and Head of Clinical Imaging, Merck Research Labs along with Dr Matthew Silva, Executive Vice President, Scientific Applications, Invicro discuss innovations in IO imaging.  

Together, Dr Goldmacher and Dr Silva address:

The evolution of treatment response criteria in immuno-oncologyNovel Tracers: Monitoring tumor or immune cell populations with imagingRadiomics, AI and Digital Biomarkers

Join us February 26-28, 2020 in NYC for the 6th annual Immuno-Oncology 360° Summit where we will continue to expand on imaging aspects for cancer immunotherapy. To learn more visit www.theconferenceforum.org

The 2nd annual Drug Delivery West (DDW) Summit provides a west coast venue for biotech, pharma and drug delivery companies to address scientific and business solutions for the best routes of delivery across different therapeutic areas with an emphasis on emerging technologies and to prepare for the future of R&D and clinical care. This podcast discusses who will be presenting and the topics covered at the summit taking place May 6-7, 2019 at the Marines' Memorial Club and Hotel in San Francisco, CA

Modernizing Clinical Trials with IQVIA's Dr Cynthia Verst

Host: Valerie Bowling, Executive Director, Pharma Talk Radio and DPharm:Disrupting Clinical Trials

Guest: Dr Cynthia Verst, President, Design and Delivery Innovation for the Research & Development Solutions organization at IQVIA

In this podcast, Valerie Bowling, Executive Director of the Conference Forum, interviews Dr Laura Esserman, breast cancer surgeon and researcher at the University of California, San Francisco. Dr Esserman shares her thoughts on how we can move towards uniting care and clinical research and the future of how medicine should be practiced.

This discussion was presented at the inaugural Drug Delivery West conference in 2018.

One of the key challenges in global health is ensuring safe and effective delivery of life saving interventions to remote and non-clinical settings. The Bill & Melinda Gates Foundation invests in technologies, which will help achieve this goal. Learn about an RFP they are launching to indentify new ideas for delivering lyophilized products and how you can participate.

Presented by David Robinson, PhD, Deputy Director, The Bill & Melinda Gates Foundation

 

To learn more about the 2019 Drug Delivery West conference taking place May 6-7, 2019 in San Francisco, CA, please click here.